Phaseline

Companies › Gracell Biotechnologies (Shanghai)

Gracell Biotechnologies (Shanghai): clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 1; Immunology, Metabolic and endocrine, Oncology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GC012F
BCMA/CD19 dual CAR-T cell therapy
TNFRSF17, CD19, BCMAPhase 1Multiple Myeloma; Refractory Systemic Lupus Erythematosus; Relapsed/Refractory AL AmyloidosisFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06235229GC012FPhase 1Multiple MyelomaOncologyMar 2026
NCT06530849GC012FPhase 1Refractory Systemic Lupus ErythematosusImmunologyFeb 2027
NCT07250269GC012FPhase 1Relapsed/Refractory AL AmyloidosisMetabolic and endocrineNov 2028

Targets

TNFRSF17 (1) CD19 (1) BCMA (1)

Companies with the same targets

Chongqing Precision Biotech Bristol-Myers Squibb Gilead Sciences Johnson & Johnson (Janssen) iCell Gene Therapeutics AstraZeneca Allogene Therapeutics Miltenyi Biomedicine Kali Therapeutics Roche

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.